[LEGISLATIVE UPDATE] H.R. 1801: Cancer Drug Coverage Parity Act of 2013

H.R. 1801: Cancer Drug Coverage Parity Act of 2013 To amend the Employee Retirement Income Security Act of 1974, the Public Health Service Act, and the Internal Revenue Code of 1986 to require group and individual health insurance coverage and group health plans to provide for coverage of oral anticancer drugs on terms no less … Continue reading

[LEGISLATIVE UPDATE] H.R. 3877: Lymphedema Treatment Act

H.R. 3877: Lymphedema Treatment Act To amend title XVIII of the Social Security Act to provide for Medicare coverage of certain lymphedema compression treatment items as items of durable medical equipment. New Cosponsor: Rep. Zoe Lofgren [D-CA19] Thank you to the newest Cosponsors.  Please thank your legislators for supporting legislation that YOU believe in.  If … Continue reading

Cancer Treatment Parity Act

Cancer Treatment Parity Act In a rare display of bipartisanship, the end of 2013 saw the holiday spirit overtake politics, as U.S. Senators Al Franken (D-MN) and Mark Kirk (R-IL) introduced the Cancer Treatment Parity Act of 2013. The bill’s goal is to provide access to better cancer treatments by leveling the costs of certain chemotherapy … Continue reading

[LEGISLATIVE UPDATE] Addressing the Quality of Life for Childhood Cancer Survivors

H.R. 2058: Childhood Cancer Survivors’ Quality of Life Act of 2013 – To improve and enhance research and programs on childhood cancer survivorship, and for other purposes. Childhood Cancer Survivors’ Quality of Life Act of 2013 – Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to make … Continue reading

[LEGISLATIVE UPDATE] Improving Cancer Treatment Act

H.R. 1661: Improving Cancer Treatment Education Act of 2013 – To amend title XVIII of the Social Security Act to provide comprehensive cancer patient treatment education under the Medicare program and to provide for research to improve cancer symptom management. Improving Cancer Treatment Education Act of 2013 – Amends title XVIII (Medicare) of the Social … Continue reading

[ADVOCACY] Empowing Americans to Fight Back Against Cancer

It’s time to treat the cancer patient too, not just the disease. This week the American Cancer Society launched a new campaign to improve the quality of life for cancer patients. The story is all too familiar: The pain, nausea and fatigue from treatment were terrible No one sat down with me to clearly explain … Continue reading

[LEGISLATIVE UPDATE] H.R. 1801: Cancer Drug Coverage Parity Act

H.R. 1801: Cancer Drug Coverage Parity Act of 2013 – To amend the Employee Retirement Income Security Act of 1974, the Public Health Service Act, and the Internal Revenue Code of 1986 to require group and individual health insurance coverage and group health plans to provide for coverage of oral anticancer drugs on terms no … Continue reading

[LEGISLATIVE UPDATE] Planning Actively for Cancer Treatment (PACT) Act

H.R. 2477: Planning Actively for Cancer Treatment (PACT) Act of 2013 – To amend title XVIII of the Social Security Act to provide for coverage of cancer care planning and coordination under the Medicare program. New Cosponsor: Rep. Donald Payne [D-NJ10] Thank you to our newest Cosponsors.  Please thank your legislators for supporting legislation that … Continue reading

Impasse Implications Impact Illness: Federal Shutdown Has Real Consequences on Patients With Cancer & Nurses

Federal Shutdown Has Real Consequences on Patients With Cancer  and Their Nurses   As the U.S. Congress continues to debate the details of the federal budget, Americans with cancer are stuck in limbo. The Oncology Nursing Society (ONS) has urged elected officials to find a resolution with appropriate funding for healthcare providers and patients with … Continue reading

Perjeta Granted Accelerated Approval for Neoadjuvant Breast Cancer

Today, the FDA granted accelerated approval to Perjeta (pertuzumab; Genentech) as part of a neoadjuvant treatment regimen for patients with high-risk, HER2-positive, early-stage breast cancer.  Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer, and the first to be approved based on pathologic complete response data. Read more: http://www.chemotherapyadvisor.com/perjeta-granted-accelerated-approval-for-neoadjuvant-breast-cancer/article/314031/?DCMP=EMC-CTA_Front&CPN=&spMailingID=7069369&spUserID=MjI1ODk5NzA1NTQS1&spJobID=90921269&spReportId=OTA5MjEyNjkS1